Find News

Filter articles

Applied Filters

Showing 51 to 60 of 706 results

CJEU opinion on SPC referral is ‘overdue’, say lawyers

EU, UK05-03-2019

An opinion on whether a supplementary protection certificate can be granted to an owner of a drug patent when the marketing authorisation is held by a third party is overdue, lawyers told WIPR.

USITC to investigate Daewoong following Allergan complaint


The US International Trade Commission has begun an investigation into Daewoong Pharmaceuticals of South Korea and California-based Evolus, following a complaint from Allergan.

Judge orders Boehringer to disclose Humira biosimilar plans


A US judge has ordered Boehringer Ingelheim to release its rollout plans for a biosimilar version of Humira (adalimumab), following a request from AbbVie.

Merck to buy immunotherapy company for $300m


US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.

Roche to make $4.3bn gene therapy acquisition


Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

DLA Piper hires two patent litigators in New York


DLA Piper has hired two patent litigators as partners in the firm’s IP and technology practice.

Clarivate announces new Life Science Alliances programme


Global information company Clarivate Analytics has launched a “Life Science Alliances Program” to provide drug and medical device developers a new way to advance their research and development.

University of California to be granted CRISPR patent


The University of California will soon be granted a patent related to the gene-editing technology CRISPR, according to a notice of allowance by the US Patent and Trademark Office.

Victory for Mayo in neurological disorder patent dispute


In a victory for Mayo Collaborative Services, a US Court has ruled that four claims in a patent, of which Athena Diagnostics is the exclusive licensee, are invalid.

Celgene signs $1bn deal to develop blood cancer therapy

Canada, US31-01-2019

Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.

Showing 51 to 60 of 706 results